About Us
With more than 20 years of providing care, our most important finding is success is more than writing a prescription. Patient support and positioning is critical.

Duluth, MNThis Parkinson’s disease care approach, known to be called the Hinz Protocol™, started in 1997 at the Morgan Park Medical Clinic in Duluth, Minnesota. We began by exploring the known association between over 200 diseases and inadequate levels of dopamine or serotonin. These patients were not suffering from a drug deficiency; they were suffering from a nutritional deficiency. Specifically, a relative nutritional deficiency of the nutrients that the body uses to make serotonin and dopamine.

Since the year 2000, our doctors who are certified to teach AMA category 1 post-graduate medical education have hosted over 100 medical conferences. Currently, over 650 doctors use this approach in their medical practice.

In 2001 the first Parkinson’s patient was successfully cared for with this approach. In 2013, we decided to focus on the most debilitating and difficult disease to treat, Parkinson’s disease. Twenty years of experience treating patients with nutrients such as L-dopa gave us a profound insight into how to place Parkinson’s disease patients in a state where the progression of the disease is slowed or halted, and the patient experiences optimal relief of symptoms.

Parkinson’s disease patients, the first three years after being diagnosed, achieve the best results. The chief priority is to halt the progression of the disease. Doing this as early as possible is associated with superior long-term results. These early on patients tend to be distracted by other forms of medical care. While drugs can give good relief of symptoms for one or two years, the whole time, they are destroying the patient’s system, making Parkinson’s disease worse, increasing the risk of death, and causing nutritional collapse. The next priority is optimizing relief of symptoms. The sad part is most patients that contact us are many years into the progression of this relentless brain deteriorating disease. They contact us because they are getting scared, not able to find a satisfactory method of traditional treatment. It makes no difference if the diagnosis has been there two years to seven years, we can help.

Caring for dopamine and serotonin-related diseases runs the spectrum from very easy (such as migraine headaches and fibromyalgia) to Parkinson’s disease which is very difficult. The primary driving force behind our doctors treating Parkinson’s disease is the gratifications they achieve as they see the most effective patient results possible happen.

The list below is a sampling of the various diseases that may respond to this approach:

List

For more information on your approach to Parkinson’s disease send an email to This email address is being protected from spambots. You need JavaScript enabled to view it. or call +01-218-626-2220 (877-626-2220). After you send your email, we may ask for more information. All communications will be kept confidential. If you have any questions, please call us free of charge.

 

The following are the peer-reviewed scientific papers we have published. Do a Google search using the article name to downloads a full-text version of each article.

  1. Trachte, G. Uncini, T. Hinz, M, Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population Neuropsychiatric Disease and Treatment, 2009, 5:227–2358.

  2. Hinz, M. Depression In: Kohlstadt I. editor. Food and Nutrients in Disease Management CRC Press; 2009, 465-481

  3. Hinz, M. Stein, A, Uncini T. The dual-gate lumen model of renal monoamine transport Neuropsychiatric Disease and Treatment, 2010, 6 387–392
  4. Hinz, M. Stein, A, Trachte, G, Uncini T. Neurotransmitter testing of the urine; a comprehensive analysis. Open Access Journal of Urology 2010:2 177–183

  5. Hinz, M. Stein, A. Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole, NeuroPsychiatric Disease and Treatment Neuropsychiatric Disease and Treatment: 2010, 6:741–747

  6. Stein, A. Hinz, M. Uncini T. Amino acid responsive Crohn’s disease, a case study. Clinical and Experimental Gastroenterology 2010:3 171–177

  7. Hinz, M. Stein A. Uncini T. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation Neuropsychiatric Disease and Treatment 2011:7 31–38

  8. Hinz, M. Stein, A. Uncini T. Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine Open Access Journal of Urology 2011:3 19–24

  9. Hinz, M. Stein, A. Uncini T. Amino acid management of Parkinson disease: A case study International Journal of General Medicine 2011:4 1–10

  10. Hinz, M. Stein, A. Uncini T. Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model” International Journal of Nephrology and Renovascular Disease 2011:4 101–113

  11. Stein, A. Hinz, M. Uncini T. Microperforation prolotherapy: a novel method for successful nonsurgical treatment of atraumatic spontaneous anterior sternoclavicular subluxation, with an illustrative case Open Access Journal of Sports Medicine 2011:2 47–52

  12. Hinz, M. Stein, A. Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction Neuropsychiatric Disease and Treatment 2011 2011:7 1–7

  13. Hinz, M. Stein, A. Uncini T. Monoamine depletion by reuptake inhibitors International Drug, Healthcare and Patient Safety 2011:3 69–77

  14. Hinz, M. Stein, A. Uncini T. The discrediting of the monoamine hypothesis International Journal of General Medicine 2012:5 135–142

  15. Hinz, M. Stein, A. Uncini T. Relative nutritional deficiencies associated with centrally acting monoamines. International Journal of General Medicine approved March 2012 for publication status in press.

  16. Hinz, M. Stein, A. Uncini T. 5-HTP efficacy and contraindications. International Journal of General Medicine 2012:5 413–430

  17. Hinz, M. et. al. Administration of Supplemental L-tyrosine with Phenelzine: A Clinical Literature Review. Clinical Pharmacology: Advances and Applications 2014:6 107–110 22 July 2014

  18. Hinz, M. et. al. Management of L-dopa overdose in the competitive inhibition state Drug, Healthcare and Patient Safety 2014:6 93–99 22 July 2014

  19. Hinz M. et. al. The Parkinson’s disease death rate Clinical Pharmacology: Advances and Applications 2014:6 161–169 21 October 2014

  20. Hinz, M. et. al. Parkinson’s disease: nausea and dyskinesia Clinical Pharmacology: Advances and Applications 2014:6 189–194 14 November 2014

  21. Hinz, M. et. al. Parkinson’s disease-associated melanin steal Neuropsychiatric Disease and Treatment 2014:10 2331–2337 10 December 2014

  22. Hinz, M. et. al. Parkinson’s disease managing reversible neurodegeneration Neuropsychiatric Disease and Treatment 2016:12 763–775 5 April, 2016

Would you like more information on our unique approach to Parkinson's disease care?